Breaking News Instant updates and real-time market news.

LGND

Ligand

$210.86

10.8 (5.40%)

04:55
10/17/18
10/17
04:55
10/17/18
04:55

Ligand management to meet with Craig Hallum

Meeting to be held in Canada on October 17 hosted by Craig Hallum.

  • 17

    Oct

  • 18

    Oct

  • 06

    Nov

LGND Ligand
$210.86

10.8 (5.40%)

08/17/18
08/17/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Dare Bioscience (DARE) initiated with a Buy at Maxim. 2. WillScot (WSC) initiated with an Outperform at Credit Suisse. 3. Ligand (LGND) initiated with a Neutral at Goldman Sachs. 4. Cott Corp. (COT) initiated with an Action List Buy at TD Securities. 5. Azure Power (AZRE) initiated with a Buy at Janney Montgomery Scott. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/11/18
ARGS
09/11/18
NO CHANGE
Target $300
ARGS
Buy
Ligand price target raised to $300 from $260 at Argus
Argus analyst Jasper Hellweg raised his price target on Ligand Pharmaceuticals to $300 and kept his Buy rating, saying that valuation is more in line with the Price/Earnings to Growth industry average ratio of 1.7-times. The analyst notes that the company is "on track" to post solid earnings growth over the period of the next several years thanks to its primary products of Promacta for clotting and Kyprolis for melanoma. Hellweg adds that Ligand also offers a "strong pipeline of new products" having partnered with over 100 pharmaceutical and biotech companies, with over 170 programs under license or in clinical development at this time. The analyst further points to the company's "clean" balance sheet and a "promising" technical pattern of its stock price.
09/19/18
HCWC
09/19/18
NO CHANGE
Target $270
HCWC
Buy
Ligand price target raised to $270 from $257 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Ligand Pharmaceuticals (LGND) to $270 after Viking Therapeutics (VKTX) announced that VK2809 Phase 2 data in nonalcoholic fatty liver disease and elevated LDL-cholesterol hit their endpoints "in a significant fashion." The analyst believes VK2809 represents an important value driver for Ligand. Currently, Ligand owns approximately 10.4% of Viking's shares outstanding and if approved, Ligand is also entitled to tiered royalties of 3.5%-7.5% of VK2809 sales, Pantginis tells investors in a research note partially titled "Viking, Value, and Ligand; a Nice Match." He keeps a Buy rating on Ligand.
10/02/18
HCWC
10/02/18
NO CHANGE
Target $280
HCWC
Buy
Ligand price target raised to $280 from $270 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Ligand Pharmaceuticals (LGND) to $280 after Viking Therapeutics (VKTX) and investigators presented updated VK5211 data in an oral plenary presentation at the American Society of Bone and Mineral Research meeting. VK5211 produces significant muscle growth in hip fracture patients and treated patients experienced overall weight gain, with loss of body fat, Pantginis tells investors in a research note. The analyst believes the chances for an outright acquisition of Viking has increased with VK2809 and VK5211 having the potential to address very large markets. He keeps a Buy rating on Ligand.

TODAY'S FREE FLY STORIES

HXL

Hexcel

$62.38

-0.7 (-1.11%)

16:24
10/22/18
10/22
16:24
10/22/18
16:24
Earnings
Hexcel raises FY18 revenue guidance to $2.14B-$2.2B from $2.1B-$2.2B 

FY18 consensus is $2.19B.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

UBER

Uber

$0.00

(0.00%)

, SFTBY

SoftBank; also use SFTBF

$0.00

(0.00%)

16:23
10/22/18
10/22
16:23
10/22/18
16:23
Periodicals
Uber's head of corporate development resigns, WSJ reports »

The head of Uber…

UBER

Uber

$0.00

(0.00%)

SFTBY

SoftBank; also use SFTBF

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HXL

Hexcel

$62.38

-0.7 (-1.11%)

16:23
10/22/18
10/22
16:23
10/22/18
16:23
Earnings
Hexcel narrows FY18 adjusted EPS view to $2.99-$3.07 from $2.96-$3.10 

FY18 consensus is $3.03.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

HNI

HNI Corporation

$38.77

0.13 (0.34%)

16:23
10/22/18
10/22
16:23
10/22/18
16:23
Earnings
HNI Corporation narrows FY18 adj. EPS view to $2.35-$2.45 from $2.35-$2.55 »

Consensus $2.45. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Nov

  • 28

    Nov

HNI

HNI Corporation

$38.77

0.13 (0.34%)

16:22
10/22/18
10/22
16:22
10/22/18
16:22
Earnings
HNI Corporation sees Q4 adjusted EPS 91c-$1.01, consensus $1.04 »

Sees Q4 organic sales up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Nov

  • 28

    Nov

HXL

Hexcel

$62.38

-0.7 (-1.11%)

16:21
10/22/18
10/22
16:21
10/22/18
16:21
Earnings
Hexcel reports Q3 EPS 80c, consensus 78c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

HNI

HNI Corporation

$38.77

0.13 (0.34%)

16:21
10/22/18
10/22
16:21
10/22/18
16:21
Earnings
HNI Corporation reports Q3 adjusted EPS 90c, consensus 86c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Nov

  • 28

    Nov

ORCL

Oracle

$47.93

0.34 (0.71%)

16:20
10/22/18
10/22
16:20
10/22/18
16:20
Initiation
Oracle initiated  »

Oracle initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 14

    Nov

RHT

Red Hat

16:20
10/22/18
10/22
16:20
10/22/18
16:20
Initiation
Red Hat initiated  »

Red Hat initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 30

    Oct

  • 13

    Nov

NOW

ServiceNow

$178.79

1.765 (1.00%)

16:20
10/22/18
10/22
16:20
10/22/18
16:20
Initiation
ServiceNow initiated  »

ServiceNow initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 06

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
10/22/18
10/22
16:20
10/22/18
16:20
Options
Closing CBOE SPX and VIX Index summary for October 22nd »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPN

Superior Energy

$8.70

-0.36 (-3.97%)

16:19
10/22/18
10/22
16:19
10/22/18
16:19
Earnings
Superior Energy reports Q3 EPS (14c), consensus (12c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

PVTL

Pivotal Software

$18.75

0.59 (3.25%)

16:19
10/22/18
10/22
16:19
10/22/18
16:19
Initiation
Pivotal Software initiated  »

Pivotal Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQ

Equillium

$14.33

0.33 (2.36%)

16:19
10/22/18
10/22
16:19
10/22/18
16:19
Hot Stocks
Breaking Hot Stocks news story on Equillium »

Partner Fund Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYKE

Sykes Enterprises

$30.67

0.63 (2.10%)

16:19
10/22/18
10/22
16:19
10/22/18
16:19
Hot Stocks
Sykes Enterprises to acquire Symphony Ventures Limited for $69M »

Sykes Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

ACC

American Campus

$39.66

-0.63 (-1.56%)

16:18
10/22/18
10/22
16:18
10/22/18
16:18
Earnings
American Campus narrows FY18 FFO view to $2.42-$2.45 from $2.40-$2.46 

consensus $2.32

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 07

    Nov

MC

Moelis

$50.66

-0.21 (-0.41%)

16:18
10/22/18
10/22
16:18
10/22/18
16:18
Earnings
Moelis reports Q3 adjusted EPS 62c, consensus 63c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

RH

RH

$109.10

-13.485 (-11.00%)

16:17
10/22/18
10/22
16:17
10/22/18
16:17
Initiation
RH initiated  »

RH initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEAM

Atlassian

$72.62

2.44 (3.48%)

16:17
10/22/18
10/22
16:17
10/22/18
16:17
Initiation
Atlassian initiated  »

Atlassian initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACC

American Campus

$39.66

-0.63 (-1.56%)

16:17
10/22/18
10/22
16:17
10/22/18
16:17
Earnings
American Campus reports Q3 FFO 44c, consensus 43c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 07

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
10/22/18
10/22
16:17
10/22/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FRBA

First Bank

$12.42

0.015 (0.12%)

16:16
10/22/18
10/22
16:16
10/22/18
16:16
Earnings
First Bank reports Q3 EPS 28c, consensus 25c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

COLM

Columbia Sportswear

$87.25

1.44 (1.68%)

, WSM

Williams-Sonoma

$58.49

-0.36 (-0.61%)

16:16
10/22/18
10/22
16:16
10/22/18
16:16
Hot Stocks
Columbia Sportswear names former Gap CFO Simmons to board »

Columbia Sportswear…

COLM

Columbia Sportswear

$87.25

1.44 (1.68%)

WSM

Williams-Sonoma

$58.49

-0.36 (-0.61%)

ELF

e.l.f. Beauty

$10.88

0.48 (4.62%)

GPS

Gap

$26.16

0.88 (3.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 28

    Oct

  • 05

    Nov

  • 03

    Mar

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
10/22/18
10/22
16:16
10/22/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IT

Gartner

$147.94

1.71 (1.17%)

16:16
10/22/18
10/22
16:16
10/22/18
16:16
Initiation
Gartner initiated  »

Gartner initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 07

    Nov

  • 08

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.